Related Experiment Video
Updated: Dec 18, 2025

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Potential risks in sentinel lymph node biopsy for cervical cancer: a single-institution pilot study
Hua Tu1,2,3, Ting Wan1,2,3, Xinke Zhang2,3,4
1Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, East Dongfeng Road 651, Guangzhou, 510060, China.
Sentinel lymph node biopsy in cervical cancer is feasible, but lymphovascular invasion impacts detection success. Undetected metastases pose a risk, potentially requiring further lymphadenectomy.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Pathology
Background:
- Sentinel lymph node (SLN) biopsy is a common oncological surgery technique.
- The risks associated with SLN biopsy in cervical cancer patients are not well understood.
Purpose of the Study:
- To evaluate the feasibility and outcomes of sentinel lymph node biopsy in cervical cancer.
- To identify factors influencing SLN detection and metastasis in cervical cancer patients.
Main Methods:
- Seventy-five cervical cancer patients underwent SLN biopsy and pelvic lymphadenectomy.
- SLNs were identified, and all resected nodes were analyzed for metastases.
- Clinicopathologic features, SLN detection rates, and metastasis distribution were assessed.
Main Results:
- SLN detection was successful in 92.0% of patients (bilateral in 33, unilateral in 36).
- Lymphovascular invasion was the sole factor negatively impacting SLN detection and increasing metastasis risk (40.9% vs 3.8%).
- Obturator nodes were most frequently involved (81.8%), with parametrial nodes also showing high positivity (36.4%).
Conclusions:
- Lymphovascular invasion significantly hinders successful SLN detection in cervical cancer.
- A high risk of undetected metastasis exists when SLNs are positive, suggesting the need for additional lymphadenectomy.
More Related Videos
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
07:51The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019